Item 7.01 |
Regulation FD Disclosure.
|
On September 22, 2022, Renovacor, Inc. (the “Company,” or
“Renovacor”) updated information reflected in a slide presentation,
which is attached as Exhibit 99.1 to this Current Report on Form
8-K and is incorporated
herein by reference. Representatives of the Company will use the
updated presentation in various meetings from time to time.
The information furnished pursuant to Item 7.01, including Exhibit
99.1, shall not be deemed “filed” for purposes of Section 18
of the Exchange Act, or otherwise subject to the liabilities of
that section, and shall not be deemed to be incorporated by
reference in any filing under the Securities Act or Exchange Act,
except as expressly set forth by specific reference in such
filing.
Important Additional Information Regarding the Transaction Will Be
Filed With the SEC
In connection with the proposed transaction between Renovacor and
Rocket Pharmaceuticals, Inc. (“Rocket”), Renovacor and Rocket will
file relevant materials with the SEC, including a Rocket
registration statement on Form S-4 that will include a
joint proxy statement of Renovacor and Rocket and will also
constitute a prospectus of Rocket, and a definitive proxy statement
will be mailed to stockholders of Renovacor and Rocket,
respectively. INVESTORS AND SECURITY HOLDERS OF RENOVACOR AND
ROCKET ARE URGED TO READ THE PROSPECTUS/JOINT PROXY STATEMENT THAT
WILL BE INCLUDED IN THE REGISTRATION STATEMENT ON FORM S-4, AND OTHER RELEVANT
DOCUMENTS FILED OR TO BE FILED WITH THE SEC IN CONNECTION WITH THE
PROPOSED TRANSACTION OR INCORPORATED BY REFERENCE IN THE
PROSPECTUS/JOINT PROXY STATEMENT (IF ANY) CAREFULLY AND IN THEIR
ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN
IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, THE PARTIES
TO THE PROPOSED TRANSACTION AND THE RISKS ASSOCIATED WITH THE
PROPOSED TRANSACTION. Investors and security holders will be able
to obtain, without charge, a copy of the registration statement,
the prospectus/joint proxy statement and other relevant documents
filed with the SEC (when available) from the SEC’s website at
http://www.sec.gov. Copies
of the documents filed with the SEC by Renovacor will be available
free of charge on Renovacor’s internet website at www.renovacor.com under the
tab “Investor & Media - Financials” or by contacting
Renovacor’s Investor Relations Department at investors@renovacor.com. Copies
of the documents filed with the SEC by Rocket will be available
free of charge on Rocket’s internet website at www.rocketpharma.com under
the tab “Investors - SEC Filings”.
Participants in the Solicitation
Renovacor, Rocket and certain of their directors, executive
officers and other members of management may be deemed to be
participants in the solicitation of proxies with respect to the
proposed transaction. Information regarding the persons who may,
under the rules of the SEC, be deemed participants in the
solicitation of the shareholders of Renovacor or Rocket in
connection with the proposed transaction, including a description
of their direct or indirect interests, by security holdings or
otherwise, will be set forth in the prospectus/joint proxy
statement when it is filed with the SEC. Information regarding
Renovacor’s directors and executive officers is contained in
Renovacor’s definitive proxy statement, which was filed with the
SEC on April 14, 2022, and Renovacor’s Current Reports on
Form 8-K, filed
with the SEC on March 28, 2022 and June 3, 2022 (as
amended on June 24, 2022). Information regarding Rocket’s
directors and executive officers is contained in Rocket’s
definitive proxy statement, which was filed with the SEC on
April 29, 2022. Security holders and investors may obtain
additional information regarding the interests of such persons,
which may be different than those of Renovacor’s or Rocket’s
security holders generally, by reading the prospectus/joint proxy
statement and other relevant documents regarding the transaction,
which will be filed with the SEC. You may obtain these documents
(when they become available) free of charge through the website
maintained by the SEC at http://www.sec.gov and from
the Investor Relations websites of Rocket or Renovacor as described
above.